Overcoming Resistance - Omission of Radiotherapy for Low-Risk Breast Cancer.
Alice Y Ho, Jennifer R Bellon
https://pubmed.ncbi.nlm.nih.gov/36791166/Actively Recruiting
Led by NRG Oncology · Updated on 2026-04-23
1670
Participants Needed
832
Research Sites
533 weeks
Total Duration
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
CONDITIONS
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
D
Director Department of Regulatory Affairs
N
Norman Wolmark, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
NRG Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Breast Radiation + Endocrine Therapy | Endocrine Therapy Only |
|---|---|---|
| What it is | Combination of external beam breast radiation (whole-breast or partial-breast irradiation) given after lumpectomy, plus 5 or more years of endocrine therapy (such as tamoxifen or aromatase inhibitor). | Endocrine therapy alone (such as tamoxifen or aromatase inhibitor) delivered for at least 5 years after lumpectomy; no post-surgery breast radiation given. |
| Role in the trial | Serves as the standard treatment arm; participants receive both radiation and endocrine therapy per usual guidelines for women with low-risk, ER/PR-positive, HER2-negative, node-negative, Stage I breast cancer. | Tests whether radiation can be omitted when patients receive only endocrine therapy after lumpectomy; evaluates a less intensive regimen for very low-risk cases. |
| Primary use | Reduces risk of local breast tumor recurrence after conservative surgery for low-risk, early-stage, hormone receptor–positive breast cancer. | Aims to control breast cancer risk and avoid recurrence after surgery using only endocrine therapy, testing if radiation can be safely avoided in eligible patients. |
| How it is given or performed | Radiation starts within 12 weeks of the last breast surgery and may be delivered as whole-breast irradiation, partial-breast irradiation, or accelerated partial-breast irradiation, followed by at least 5 years of oral endocrine therapy (tamoxifen or aromatase inhibitor). Endocrine treatment can start before, during, or after radiation. | Endocrine therapy (tamoxifen or aromatase inhibitor), started after surgery, is taken daily by mouth for at least 5 years. No additional breast radiation is provided. |
| Evidence status | Supported by decades of randomized trials showing reduced local recurrence with radiation plus endocrine therapy after breast-conserving surgery for women fitting these criteria. | For selected patients with low-risk tumor biology, several studies suggest that omitting radiation therapy results in only a modestly increased risk of local recurrence when taking endocrine therapy, with little to no difference in overall survival. |
| Important limitations | Risk of short-term and long-term side effects from radiation, including skin changes, fatigue, and rare long-term complications. Not all low-risk patients may require radiation for adequate control. | Omitting radiation may increase the risk of local breast cancer recurrence compared to combined treatment, even in very low-risk tumors. Ongoing trials are confirming the safety of this de-escalated approach. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 5 years
Participants receive either breast radiation therapy plus endocrine therapy or endocrine therapy alone for hormone sensitive breast cancer. Radiation therapy begins within 12 weeks after surgery, and endocrine therapy is taken for a minimum of 5 years.
Visits scheduled as per treatment plan and follow-up needs
Duration - Up to 15 years
Participants are monitored for breast cancer recurrence and overall health following treatment completion.
Periodic visits over the long-term monitoring period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alice Y Ho, Jennifer R Bellon
https://pubmed.ncbi.nlm.nih.gov/36791166/NRG Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor